A late-stage trial showed Bristol-Myers Squibb's hepatitis C combination therapy daclatasvir and asunaprevir cured 90% of previously untreated patients with genotype 1b virus after 24 weeks of therapy. The drug also cured 82% of patients who couldn't tolerate interferon and ribavirin, the older standard treatments for the disease. "Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease," lead investigator Michael Manns said. The drug combo has already been submitted for FDA review.
Published in Brief: